LUC00065I2 - - Google Patents

Download PDF

Info

Publication number
LUC00065I2
LUC00065I2 LU00065C LUC00065C LUC00065I2 LU C00065 I2 LUC00065 I2 LU C00065I2 LU 00065 C LU00065 C LU 00065C LU C00065 C LUC00065 C LU C00065C LU C00065 I2 LUC00065 I2 LU C00065I2
Authority
LU
Luxembourg
Prior art keywords
cladribine
cyclodextrin
compositions
oral administration
especially suited
Prior art date
Application number
LU00065C
Other languages
English (en)
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of LUC00065I1 publication Critical patent/LUC00065I1/fr
Publication of LUC00065I2 publication Critical patent/LUC00065I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
LU00065C 2003-03-28 2018-02-12 LUC00065I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45892203P 2003-03-28 2003-03-28
US48475603P 2003-07-02 2003-07-02
US54124704P 2004-02-04 2004-02-04
PCT/US2004/009387 WO2004087101A2 (fr) 2003-03-28 2004-03-26 Formulations de cladribine a administration par voie orale

Publications (2)

Publication Number Publication Date
LUC00065I1 LUC00065I1 (fr) 2018-02-14
LUC00065I2 true LUC00065I2 (fr) 2018-03-28

Family

ID=33135982

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00065C LUC00065I2 (fr) 2003-03-28 2018-02-12

Country Status (28)

Country Link
US (2) US7888328B2 (fr)
EP (1) EP1608344B1 (fr)
JP (1) JP5256611B2 (fr)
KR (1) KR101129816B1 (fr)
AT (1) ATE476177T1 (fr)
AU (2) AU2004226437B2 (fr)
BR (2) BR122018068797B1 (fr)
CA (1) CA2520523C (fr)
CY (2) CY1112591T1 (fr)
DE (1) DE602004028448D1 (fr)
DK (2) DK2272503T3 (fr)
EA (1) EA009944B1 (fr)
ES (1) ES2409884T3 (fr)
HK (2) HK1089654A1 (fr)
HR (1) HRP20050925A2 (fr)
HU (1) HUS1800013I1 (fr)
IL (1) IL213853A0 (fr)
IS (1) IS2799B (fr)
LT (1) LTC1608344I2 (fr)
LU (1) LUC00065I2 (fr)
ME (1) ME00249B (fr)
MX (1) MXPA05010329A (fr)
NO (1) NO20054945L (fr)
PL (1) PL1608344T3 (fr)
PT (1) PT1608344E (fr)
RS (2) RS20050735A (fr)
SG (1) SG175450A1 (fr)
WO (1) WO2004087101A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912615B (zh) * 2003-03-28 2013-03-27 阿莱斯贸易有限公司 用于改善的经口和透粘膜输送的克拉屈滨制剂
SI2805723T1 (en) 2004-12-22 2018-02-28 Merck Serono Sa Cladribine regimen for the treatment of multiple sclerosis
US9925151B2 (en) * 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EP2343074A1 (fr) 2009-12-23 2011-07-13 Merck Serono S.A. Utilisation d'analogues de la purine pour traiter des maladies des voies respiratoires
EP2428201A1 (fr) 2010-09-08 2012-03-14 Merck Serono S.A. Administration orale de nucléosides monophosphates
WO2012097867A1 (fr) 2011-01-18 2012-07-26 Synthon Bv Particules de cladribine et compositions pharmaceutiques comprenant celles-ci
CA3083328A1 (fr) 2017-11-24 2019-05-31 Merck Patent Gmbh Regime de cladribine destine a etre utilise dans le traitement de formes progressives de la sclerose en plaques
EP3628310A1 (fr) 2018-09-25 2020-04-01 Synbias Pharma AG Composition pharmaceutique comprenant des dispersions solides de cladribine amorphe et support hydrosoluble pharmaceutiquement acceptable
RU2748311C1 (ru) * 2020-01-29 2021-05-21 Общество с ограниченной ответственностью "ФармЭко" Фармацевтическая композиция, содержащая твердые дисперсии аморфного кладрибина и фармацевтически приемлемый водорастворимый носитель
MX2023002843A (es) 2020-09-10 2023-03-31 Merck Patent Gmbh Nuevo regimen de tratamiento para el tratamiento de trastornos autoinmunitarios.
AU2022231384A1 (en) 2021-03-03 2023-09-14 Ares Trading S.A. Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods
RU2758436C1 (ru) * 2021-04-05 2021-10-28 Общество с ограниченной ответственностью «ФармЭко» Способ получения аморфных ко-эвапоратов кладрибина с циклодекстринами
WO2022229761A1 (fr) * 2021-04-28 2022-11-03 Biophore India Pharmaceuticals Pvt Ltd Forme solide d'un complexe de 2-chloro-2'-désoxy-adénosine avec du hβcd
WO2023242285A1 (fr) 2022-06-15 2023-12-21 Vektor Pharma Tf Gmbh Formulation sublinguale de composé anticancéreux destinée à être utilisée dans le traitement de maladies neurodégénératives auto-immunes

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
HU181703B (en) 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
JPS5838250A (ja) 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
US4383992A (en) 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58177949A (ja) 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
EP0094157B1 (fr) 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Composition pharmaceutique et son application
HU191101B (en) 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3317064A1 (de) 1983-05-10 1984-11-15 Consortium für elektrochemische Industrie GmbH, 8000 München Verfahren zur herstellung von cyclooctaamylose
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
JP2575460B2 (ja) * 1988-05-12 1997-01-22 東京田辺製薬株式会社 ダナゾール−シクロデキストリン包接化合物
DK0465535T3 (da) 1989-04-03 1999-03-01 Janssen Pharmaceutica Nv Regioselektive substitutioner i cyclodextriner
JPH035438A (ja) * 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
WO1993023058A1 (fr) 1992-05-19 1993-11-25 The Scripps Research Institute Utilisation de derives de 2-halo adenine comme agents therapeutiques agissant contre la leucemie myeloide chronique
DE4237639A1 (de) * 1992-11-07 1994-05-11 Basf Ag Verfahren zur Herstellung von Polymeren mit NLO-aktiven Seitengruppen und deren Verwendung
US5424296A (en) 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5510336A (en) 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
JP3310299B2 (ja) * 1995-11-23 2002-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 溶融−押し出しにより調製されるシクロデキストリンの固体混合物
JPH10265495A (ja) * 1997-03-25 1998-10-06 Meiji Milk Prod Co Ltd フルオロプロゲステロン誘導体包接化合物
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999042111A1 (fr) 1998-02-23 1999-08-26 Cyclops, Ehf. Complexes de cyclodextrine extremement energetiques
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
EP1084149A1 (fr) 1998-05-29 2001-03-21 Janssen Pharmaceutica N.V. Derives de cyclodextrine alkyle acyle et leur utilisation en tant qu'excipients pour medicaments
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
US6239118B1 (en) 1999-10-05 2001-05-29 Richard A. Schatz Method for preventing restenosis using a substituted adenine derivative
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures

Also Published As

Publication number Publication date
DE602004028448D1 (de) 2010-09-16
KR101129816B1 (ko) 2012-03-26
MXPA05010329A (es) 2006-05-31
PL1608344T3 (pl) 2011-01-31
US20070197468A1 (en) 2007-08-23
CY1112591T1 (el) 2016-02-10
ME00249B (fr) 2011-05-10
US20110097306A1 (en) 2011-04-28
BR122018068797B1 (pt) 2021-04-27
EA009944B1 (ru) 2008-04-28
BRPI0408848B1 (pt) 2018-11-27
HRP20050925A2 (en) 2006-08-31
ATE476177T1 (de) 2010-08-15
JP2006521403A (ja) 2006-09-21
LTPA2018502I1 (lt) 2018-03-12
CY2018005I2 (el) 2018-06-27
DK2272503T3 (da) 2013-05-21
HUS1800013I1 (hu) 2018-03-28
ES2409884T3 (es) 2013-06-28
EP1608344B1 (fr) 2010-08-04
CY2018005I1 (el) 2018-06-27
IS2799B (is) 2012-09-15
IL213853A0 (en) 2011-07-31
HK1150266A1 (en) 2011-11-18
US8785415B2 (en) 2014-07-22
LUC00065I1 (fr) 2018-02-14
EP1608344A2 (fr) 2005-12-28
CA2520523C (fr) 2011-10-11
JP5256611B2 (ja) 2013-08-07
CA2520523A1 (fr) 2004-10-14
DK1608344T3 (da) 2010-09-06
AU2004226437B2 (en) 2010-06-03
RS51115B (sr) 2010-10-31
BRPI0408848B8 (pt) 2021-07-27
HK1089654A1 (en) 2006-12-08
BRPI0408848A8 (pt) 2017-12-26
RS20050734A (en) 2008-06-05
LTC1608344I2 (lt) 2019-03-12
BRPI0408848A (pt) 2006-04-04
AU2010214777A1 (en) 2010-09-23
WO2004087101A3 (fr) 2005-02-03
MEP34308A (en) 2011-02-10
EA200600404A1 (ru) 2006-08-25
AU2004226437A1 (en) 2004-10-14
KR20060015487A (ko) 2006-02-17
US7888328B2 (en) 2011-02-15
NO20054945D0 (no) 2005-10-25
NO20054945L (no) 2005-11-24
IS8051A (is) 2005-09-28
PT1608344E (pt) 2010-09-02
SG175450A1 (en) 2011-11-28
WO2004087101A2 (fr) 2004-10-14
AU2010214777B2 (en) 2013-01-31
RS20050735A (en) 2008-06-05

Similar Documents

Publication Publication Date Title
LUC00065I2 (fr)
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
UA97502C2 (ru) Кристаллическая твердая основа разагилина
TW200732349A (en) Anti-OX40L antibodies and methods using same
AR033711A1 (es) Composiciones farmaceuticas
MXPA05010330A (es) Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa.
ZA200604874B (en) Pharmaceutical compositions
TW200602062A (en) Improved formulations of 6-mercaptopurine
IL173929A0 (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
MY162185A (en) Alumina particles and methods of making the same
TW200531686A (en) Pharmaceutical compositions
HU0302441D0 (en) Pharmaceutical compositions having antibiothic effect
MX2008001012A (es) Productos para el cuidado bucal.
MX2009012643A (es) Particulas de alumina y metodos para fabricar las mismas.
AU2003270202A8 (en) Pharmaceutical compositions useful for the treatment of cancers
EP2272503A3 (fr) Formulation orale de cladribine
UA100984C2 (ru) Антитела против nrr notch1 и способы их применения
HK1070835A1 (en) Pharmaceutical compositions for the treatment of sars
ECSP024344A (es) Composiciones farmaceuticas